Verrica Pharmaceuticals Inc., an innovative clinical-stage dermatology therapeutics company, based in West Chester, Pennsylvania, is making strong progress in developing groundbreaking medications for treating skin diseases in the United States. The company's pioneering VP-102 product candidate, used for treating common warts and molluscum contagiosum, has recently completed a successful Phase II clinical trial for treating external genital warts. Moreover, the company is also advancing VP-315, an injectable therapy, for treating a range of dermatology oncologic conditions, including basal cell carcinoma. Verrica Pharmaceuticals also has the exciting VP-103 cantharidin-based product candidate for eradicating stubborn plantar warts. Verrica Pharmaceuticals collaborates with Torii Pharmaceutical Co., Ltd. to develop and commercialize its product candidates for the treatment of molluscum contagiosum and common warts in Japan. It also has a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. The company was established in 2013 and has quickly emerged as a leading player in the dermatology sector.
Verrica Pharmaceuticals Inc.'s ticker is VRCA
The company's shares trade on the NASDAQ stock exchange
They are based in West Chester, Pennsylvania
There are 11-50 employees working at Verrica Pharmaceuticals Inc.
It is https://verrica.com/
Verrica Pharmaceuticals Inc. is in the Healthcare sector
Verrica Pharmaceuticals Inc. is in the Biotechnology industry
The following five companies are Verrica Pharmaceuticals Inc.'s industry peers: